Davey P G, Clarkson P B, McMahon A, MacDonald T M
MEMO (Medicines Monitoring), University Department of Clinical Pharmacology, Ninewells Hospital & Medical School, Dundee, Scotland.
Pharmacoeconomics. 1999 Oct;16(4):399-407. doi: 10.2165/00019053-199916040-00007.
To investigate whether the extent of systolic dysfunction is a useful predictor of the costs of healthcare and social support for patients with heart failure.
Cross-sectional study with collection of cost data attributed to management of heart failure in the previous year.
Four primary-care practices in Scotland.
Patients receiving long term therapy with loop diuretics for suspected heart failure.
Two-dimensional and Doppler echocardiography.
Two hypotheses were tested: (i) the proportion of patients incurring costs is higher in patients with abnormal left ventricular (LV) function; and (ii) the median cost per patient that incurs costs is higher in patients with abnormal LV function. Of the 226 patients in the study, 67 (30%) had abnormal systolic function. In comparison with the remaining 159 patients, they had higher healthcare costs [560 Pounds vs 440 Pounds per patient year (1994/1995 values)], were more likely to incur hospital inpatient or outpatient costs [Odds ratio (OR): 2.02; 95% confidence interval (CI): 1.06 to 3.84] and had significantly higher primary-care costs (mean 292 Pounds vs 231 Pounds per patient year; p = 0.02, Mann Whitney test). In contrast, they were no more likely to incur social support costs (OR: 1.22; 95% CI: 0.52 to 2.86) and the mean cost of social support per patient year was lower (234 Pounds vs 373 Pounds).
Patients with objectively measured systolic dysfunction incurred significantly higher healthcare costs in the year before diagnosis. This suggests that treatment that improves systolic function will reduce healthcare costs, even in a primary-care population with relatively mild congestive heart failure.
探讨收缩功能障碍的程度是否可有效预测心力衰竭患者的医疗保健和社会支持成本。
一项横断面研究,收集上一年归因于心力衰竭管理的成本数据。
苏格兰的四家初级保健机构。
因疑似心力衰竭接受袢利尿剂长期治疗的患者。
二维和多普勒超声心动图检查。
检验了两个假设:(i)左心室(LV)功能异常的患者产生成本的比例更高;(ii)LV功能异常的患者中产生成本的每位患者的中位数成本更高。在该研究的226例患者中,67例(30%)收缩功能异常。与其余159例患者相比,他们的医疗保健成本更高[每位患者每年560英镑 vs 440英镑(1994/1995年数值)],更有可能产生住院或门诊成本[比值比(OR):2.02;95%置信区间(CI):1.06至3.84],且初级保健成本显著更高(每位患者每年平均292英镑 vs 231英镑;p = 0.02,曼-惠特尼检验)。相比之下,他们产生社会支持成本的可能性并不更高(OR:1.22;95% CI:0.52至2.86),且每位患者每年的社会支持平均成本更低(234英镑 vs 373英镑)。
经客观测量存在收缩功能障碍的患者在诊断前一年产生的医疗保健成本显著更高。这表明改善收缩功能的治疗将降低医疗保健成本,即使在患有相对轻度充血性心力衰竭的初级保健人群中也是如此。